You just read:

ArmaGen Announces Oral Presentation of Preliminary Results from its Phase 2 Clinical Trial of AGT-181 in Patients with MPS 1 to be Presented at WORLDSymposium 2017

News provided by

ArmaGen, Inc.

07 Feb, 2017, 07:00 ET